[Mechanism concerning antitumor effect of oridonin on multiple myeloma cell line U266]

Hao-Qing Duan1, Mian-Yang Li2, Li Gao3

  • 1College of Laboratorial Medicine and College of Life Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China; Department of Clinical Laboratorial Examination, Chinese PLA General Hospital, Bejing 100853, China.

Insights

Oridonin effectively inhibits human multiple myeloma U266 cell growth and induces apoptosis. This compound downregulates key genes like FGFR3, BCL2, CCND1, and MYC, offering potential for targeted multiple myeloma therapies.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Context:

  • Multiple myeloma is a hematological malignancy with limited treatment options.
  • Understanding novel therapeutic agents is crucial for improving patient outcomes.

Purpose:

  • To investigate the antitumor effects of oridonin on the human multiple myeloma cell line U266.
  • To elucidate the underlying molecular mechanisms of oridonin's action.

Summary:

  • Oridonin demonstrated significant inhibition of U266 cell proliferation in a dose- and time-dependent manner.
  • Morphological analysis revealed oridonin-induced apoptosis, confirmed by flow cytometry.
  • Oridonin treatment led to decreased mRNA and protein levels of FGFR3, BCL2, CCND1, and MYC, with a notable upregulation of P53 protein.

Impact:

  • Oridonin exhibits potent anti-multiple myeloma activity by inhibiting cell proliferation and inducing apoptosis.
  • The findings suggest oridonin as a potential candidate for targeted therapy in multiple myeloma treatment regimens.